(Q40168061)

18 September 2017

1 reference

title

Adjuvant systemic therapy in breast cancer; a review (English)

1 reference

18 September 2017

1 reference

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

8 October 2023

author name string

H. T. Mouridsen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6363091

8 October 2023

T. Palshof

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6363091

8 October 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6363091

8 October 2023

publication date

1 December 1983

1 reference

full work available at URL

18 September 2017

https://api.elsevier.com/content/article/PII:0277537983901645?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

https://api.elsevier.com/content/article/PII:0277537983901645?httpAccept=text/plain

8 October 2023

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

European Journal of Cancer & Clinical Oncology

8 October 2023

published in

1 reference

18 September 2017

19

1 reference

18 September 2017

12

1 reference

18 September 2017

1753-1770

1 reference

The curability of breast cancer

18 September 2017

1

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Combination versus single agent chemotherapy: A review of the basis for selection of drug treatment of cancer

8 October 2023

3

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Kinetics of mammary tumor cell growth and implications for therapy

8 October 2023

6

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

The scientific basis for adjuvant chemotherapy.

8 October 2023

7

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Combined chemotherapy and surgery in breast cancer: a review

8 October 2023

9

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Surgical Adjuvant Chemotherapy

8 October 2023

10

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Adjuvant chemotherapy in breast cancer

8 October 2023

11

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings

8 October 2023

12

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

8 October 2023

13

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

L-phenylalanine mustard (L-PAM) in the management of primary breast cancer:An update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU)

8 October 2023

14

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Disease-free survival at intervals during and following completion of adjuvant chemotherapy: the NSABP experience from three breast cancer protocols

8 October 2023

15

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: the Milan Institute experience

8 October 2023

16

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer

8 October 2023

18

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

CONTROLLED TRIAL OF ADJUVANT CHEMOTHERAPY WITH MELPHALAN FOR BREAST CANCER

8 October 2023

19

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Surgical adjuvant chemotherapy with mitomycin C and cyclophosphamide in Japanese patients with breast cancer

8 October 2023

20

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Adjuvant chemotherapy with four drugs for stage 2 breast cancer

8 October 2023

21

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Oral adjuvant therapy in breast carcinoma—a multicentre trial

8 October 2023

22

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Adjuvant chemoimmunotherapy with LMF plus BCG in node-negative and node-positive breast cancer - intermediate report at 4 years

8 October 2023

24

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Repeated adjuvant chemotherapy with phenylalanine mustard or 5-fluorouracil, cyclophosphamide, and prednisone with or without radiation, after mastectomy for breast cancer

8 October 2023

25

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

A randomized trial of postoperative five-versus three-drug chemotherapy after mastectomy: a Cancer and Leukemia Group B (CALGB) study

8 October 2023

27

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Estrogen-receptor status and response to chemotherapy in early and advanced breast cancer

8 October 2023

28

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

The CMF program for operable breast cancer with positive axillary nodes:Updated analysis on the disease-free interval, site of relapse and drug tolerance

8 October 2023

29

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Trials of adjuvant chemotherapy in breast cancer. The experience of the Istituto Nazionale Tumori of Milan

8 October 2023

30

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

A randomized comparative trial of chemotherapy and irradiation therapy for stage II breast cancer

8 October 2023

32

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Favorable factors in the adjuvant therapy of breast cancer

8 October 2023

33

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Combination chemotherapy (CMFVP) versus L-phenylalanine mustard (L-PAM) for operable breast cancer with positive axillary nodes: a Southwest Oncology Group Study

8 October 2023

34

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Current status and indications for adjuvant therapy in breast cancer

8 October 2023

40

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Dose-response effect of adjuvant chemotherapy in breast cancer

8 October 2023

44

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Multimodal treatment in operable breast cancer: five-year results of the CMF programme.

8 October 2023

45

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

1-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers

8 October 2023

46

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Adjuvant intermittent chemoimmunotherapy for primary breast cancer: a prospective study with immunologic follow-up

8 October 2023

49

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial

8 October 2023

50

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Follow-up adjuvant chemotherapy and chemoimmunotherapy for stage II and III carcinoma of the breast

8 October 2023

51

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

A new adjuvant treatment with polyadenylic-polyuridylic acid in operable breast cancer

8 October 2023

54

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

[The results of 5 years of ancillary chemotherapy of carcinoma of the breast (author's transl)]

8 October 2023

55

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Adverse effect of radiotherapy on adjuvant chemotherapy for carcinoma of the breast

8 October 2023

56

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Adjuvant chemotherapy in the radical treatment of carcinoma of the breast--a clinical trial

8 October 2023

57

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

TESTOSTERONE PROPIONATE THERAPY IN BREAST CANCER

8 October 2023

62

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

THERAPEUTIC CASTRATION IN THE TREATMENT OF ADVANCED BREAST CANCER

8 October 2023

63

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Estrogen receptors and breast cancer response to adrenalectomy

8 October 2023

66

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Specific estrogen binding by the cytoplasm fof human breast carcinoma.

8 October 2023

67

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Oestrogen receptor in human breast cancer tissue and response to endocrine therapy.

8 October 2023

69

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Prediction of breast cancer response to endocrine therapy

8 October 2023

71

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Estrogen receptors in human breast cancer tissue

8 October 2023

72

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Oestrogen receptors in breast cancer: a changing concept

8 October 2023

73

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Changes in multiple or sequential estrogen receptor determinations in breast cancer

8 October 2023

75

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Estrogen receptor levels in multiple biopsies from patients with breast cancer

8 October 2023

76

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Sex hormone receptors in mammary tumours of GR mice

8 October 2023

77

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer

8 October 2023

78

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

The pathogenesis of cancer metastasis

8 October 2023

81

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer

8 October 2023

82

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Estrogen receptors and response to endocrine therapy and cytotoxic chemotherapy in advanced breast cancer

8 October 2023

83

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

PROPHYLACTIC ENDOCRINE TREATMENT IN CARCINOMA OF THE BREAST

8 October 2023

89

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Antiestrogens in treatment of breast cancer

8 October 2023

95

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Tamoxifen in advanced breast cancer

8 October 2023

96

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

CMF versus CMF plus tamoxifen in advanced breast cancer in postmenopausal women. An EORTC trial

8 October 2023

99

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Adjuvant therapy of stage II breast cancer: 48-month follow-up of a prospective randomized clinical trial

8 October 2023

103

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Treatment of primary breast cancer with chemotherapy and tamoxifen

8 October 2023

107

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Chemotherapy and Tamoxifen for Breast Cancer

8 October 2023

108

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

Prognostic value of estrogen receptors in primary breast cancer

8 October 2023

109

1 reference

https://api.crossref.org/works/10.1016/0277-5379(83)90164-5

8 October 2023

Identifiers

1 reference

18 September 2017

1 reference